Statement: There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients.
Primary_evidence: Adverse Events 1:   Total: 50/198 (25.25%)   Anaemia 1/198 (0.51%)   Febrile neutropenia 1/198 (0.51%)   Leukocytosis 1/198 (0.51%)   Leukopenia 2/198 (1.01%)   Neutropenia 1/198 (0.51%)   Pancytopenia 0/198 (0.00%)   Atrial fibrillation 0/198 (0.00%)   Cardiac failure congestive 0/198 (0.00%)   Palpitations 0/198 (0.00%)   Pericardial effusion 1/198 (0.51%)   Supraventricular tachycardia 1/198 (0.51%) Adverse Events 2:   Total: 51/202 (25.25%)   Anaemia 3/202 (1.49%)   Febrile neutropenia 2/202 (0.99%)   Leukocytosis 0/202 (0.00%)   Leukopenia 0/202 (0.00%)   Neutropenia 0/202 (0.00%)   Pancytopenia 1/202 (0.50%)   Atrial fibrillation 1/202 (0.50%)   Cardiac failure congestive 1/202 (0.50%)   Palpitations 1/202 (0.50%)   Pericardial effusion 1/202 (0.50%)   Supraventricular tachycardia 1/202 (0.50%)